



September 4, 2019

✓ **BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards the Company entering into a licensing, development and commercialization agreement with Boehringer Ingelheim for its MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**

*R. V. Satam*  
For **R. V. SATAM**  
**COMPANY SECRETARY**



Encl.: a/a



## Lupin and Boehringer Ingelheim announce Partnership to Develop and Commercialize Novel Oncology Drug to treat KRAS-driven Cancers

- *Boehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreement*
- *Lupin's proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim's emerging KRAS inhibitor pipeline to address KRAS-driven cancers*
- *Lupin to receive a \$20 million upfront payment with potential total milestones of more than \$700 million and royalties on the sales of the product*

**Ingelheim, Germany and Mumbai, India – 4 September 2019** – Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer Ingelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.


Commenting on the partnership, **Nilesh Gupta, Managing Director, Lupin Limited** said, "With the success of our second new drug discovery program in oncology, we have made a significant mark in bringing novel treatments to patients. Lupin's MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program. We are delighted to partner with Boehringer Ingelheim in developing treatments that will truly benefit patients in need".

**Dr. Raj Kamboj, President of Lupin's Novel Drug Discovery and Development (NDDD)** stated, "The success of our second NDDD program in Oncology has added to our confidence in bringing highly differentiated and best-in-class innovation from India for patients globally. Carrying forward our founder, Dr. Desh Bandhu Gupta's dream in shaping true innovation, we have delivered a novel treatment from conceptualization to clinical stage development with promising results that can be a potential combination treatment for precision oncology."

"The licensing of Lupin's novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effective and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available," said **Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim**. "We believe this collaboration will significantly strengthen our KRAS program. We have developed comprehensive approaches to successfully tackle the oncogenic KRAS-RAF-MEK-ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types."

The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. KRAS mutations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 percent in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. Preclinical data has shown that the combination of Boehringer Ingelheim's novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check.





Lupin's MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients. Lupin's Novel Drug Discovery and Development team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of oncology, immunology and metabolic disorders. Lupin's NDDD activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

Lupin will receive an upfront payment of \$20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than \$700 million. Additionally, Lupin will be entitled to receive double-digit royalties on the sales of the product.

### **Boehringer Ingelheim**

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of nearly EUR 17.5 billion. R&D expenditure of almost EUR 3.2 billion, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.


More information about Boehringer Ingelheim can be found on [www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com) or in our annual report: <http://annualreport.boehringer-ingelheim.com>.

### **Boehringer Ingelheim in Oncology**

Cancer takes. Takes away time. Takes away loved ones. At Boehringer Ingelheim Oncology, we are giving patients new hope, by taking cancer on. We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immuno-oncology therapies and intelligent combination approaches to help combat many cancers.

### **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.



Lupin is the 8<sup>th</sup> largest generics pharmaceutical company by revenues (31<sup>st</sup> Mar 2019, Bloomberg LTM) respectively. The Company is the 3<sup>rd</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31<sup>st</sup> Mar 2019, Bloomberg LTM); 5<sup>th</sup> largest generic pharmaceutical player in Japan and 6<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31<sup>st</sup> March, 2019, Lupin's Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter – [www.twitter.com/lupinglobal](http://www.twitter.com/lupinglobal)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

#### **Media Contacts:**

##### **Boehringer Ingelheim**

Dr. Reinhard Malin  
Head of Communications Innovation Unit  
Boehringer Ingelheim Corporate Center GmbH  
Media + PR  
P: +49 6132 77-90815  
[reinhard.malin@boehringer-ingelheim.com](mailto:reinhard.malin@boehringer-ingelheim.com)

Linda Ruckel  
Associate Director, Media and Corporate Reputation  
Boehringer Ingelheim U.S.  
Media + PR  
P: + 203-791-6672  
[linda.ruckel@boehringer-ingelheim.com](mailto:linda.ruckel@boehringer-ingelheim.com)

##### **Lupin Limited**

Pooja Thakran  
VP – Corporate Communications  
Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)  
Ph: +91-22-66402531 / 9811665000

Arvind Bothra  
Head – Investor Relations  
Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)  
Ph: +91-22-66408237